Press release
CellNet™ wins 2026 Edison Silver and R&D 100 Awards
Two international awards for the water-free, solvent-free process Sangtech uses to make CellNet™ filter media.
In brief
- CellNet™ received the Silver Edison Award in Energy & Climate Resiliency and a 2026 R&D 100 Award in Process/Prototyping.
- Both recognize a patented supercritical CO₂ process that modifies filter fibers without water or chemical solvents.
- CellNet™ is Sangtech Lab Inc.’s technology and trademark, developed in joint work with the Taiwan Textile Research Institute (TTRI), and made in Yilan, Taiwan.
TAIPEI, October 2, 2026. CellNet™, Sangtech Lab Inc.’s blood filtration technology, developed in joint work with the Taiwan Textile Research Institute (TTRI), has received two international awards this year: the Silver Award in the Energy & Climate Resiliency category of the 2026 Edison Awards, and a 2026 R&D 100 Award in the Process/Prototyping category.
Two awards for one process
Edison Awards 2026Silver · Energy & Climate Resiliency
R&D 100 Awards 2026Winner · Process/PrototypingThe Edison Awards recognize innovation in new products and services. CellNet™ won Silver in the Waste-to-Value Material Systems sub-category, with awards presented at the Edison Awards Gala in Fort Myers, Florida, in April 2026. The R&D 100 Awards, run by R&D World, name the year’s 100 most significant new technologies; CellNet™ was among the 2026 winners announced in August.
Filter media made without water or solvents
To make filter fibers compatible with blood, conventional manufacturing treats them in chemical baths and rinses them with large amounts of water. CellNet™ uses a patented supercritical carbon dioxide (CO₂) process instead. Under pressure, CO₂ behaves like a liquid and carries the surface chemistry into the fibers, then returns to a gas when the pressure is released.
No water or organic solvents are used and no process wastewater is produced. Sangtech estimates the process reduces the carbon footprint of media modification by about 90% compared with conventional methods.
Figure 1CellNet™ PR, the inline whole blood filter built with CellNet™ media.
Results presented at ISBT 2026
Research findings for CellNet™ were presented in June 2026 at the 39th International Congress of the International Society of Blood Transfusion (ISBT). In tests on fresh human whole blood, CellNet™ PR removed more than 99.99% of leukocytes with 91–95% red cell recovery, reduced storage microparticles by 70–83%, and kept hemolysis below the regulatory limit after 35 days of refrigerated storage (manufacturer data).
The research was carried out with National Taiwan University, National Taiwan University Hospital and Taipei Medical University, with a team that included Professor Thierry Burnouf.
“This award is not for me alone. We have been working on this technology since 1991, so it has been 35 years. International recognition shows that, even in difficult circumstances, we have found a path worth continuing.”
Tom Juan, Chairman, Sangtech Lab Inc.
Made in Taiwan
CellNet™ media is made at Sangtech’s ISO 13485 manufacturing site in Yilan, Taiwan, and built into CellNet™ PR, an inline whole blood filter for the companies that make blood collection sets. Sangtech plans to bring CellNet™ to markets in Europe and North America CellNet™ PR is the first and only commercial whole blood inline leukoreduction filter in the world manufactured without organic solvents or process wastewater.
Edison Awards. CellNet™ Leukocyte Reduction Filter, 2026 Silver, Energy & Climate Resiliency.
See all sourcesSangtech Lab Inc. CellNet™ blood filtration technology wins 2026 Edison Silver and R&D 100 Awards. Press release, October 2, 2026.
See all sourcesCellNet™ PR results on fresh human whole blood, 39th International Congress of the ISBT, June 2026 (manufacturer data), as reported in Sangtech’s press release of October 2, 2026.
See all sources